First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback